Our preclinical research and development team has been working tirelessly to advance promising new drug candidates into clinical trials. With a focus on developing first-in-class and best-in-class therapies for areas of high unmet need, we have expanded our preclinical pipeline significantly over the past year. Our goal is to translate cutting-edge science into potential new treatment options for patients.
Preclinical Assets particularly exciting area of focus has been oncology. We currently have three oncology drug candidates in advanced preclinical testing that have shown potential in animal models. The first is an immunotherapy agent that activates the immune system in a novel way to attack multiple types of solid tumors. In mouse studies, it has led to regression or stabilization of tumors when used as a monotherapy or in combination with other immunotherapies. We hope to begin clinical trials next year.
The second oncology drug candidate is a small molecule inhibitor of a novel cancer cell growth pathway. In preclinical safety and efficacy studies, it has shown the ability to halt tumor growth across a wide range of cancer cell lines representing various solid tumors and blood cancers. The molecule appears to have a favorable safety profile and we are completing the necessary IND-enabling studies to take it into the clinic in 2022.
The third potential new therapy in development is an antibody-drug conjugate that targets a receptor overexpressed in many lung, breast, and gastrointestinal cancers. By linking a cytotoxic chemotherapy agent to an antibody that homes in on the receptor, it allows selective delivery of the chemotherapy directly inside cancer cells. In mouse xenograft models, it has led to impressive tumor shrinkage without the side effects seen with traditional chemotherapy. We plan to file an IND application later this year.
Get More Insights on- Preclinical Assets
Explore More Related Article On- Artificial Insemination Market
For Deeper Insights, Find the Report in the Language that You want:
